© 1998 by Oxford University Press
Journal of the National Cancer Institute, Vol. 90, No. 20, 1552-1558,
October 21, 1998
©Copyright 1998 Oxford University Press
ARTICLES |
Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth
Affiliations of authors: R. M. O'Regan (Division of Hematology/Oncology), A. Cisneros, J. I. MacGregor, H. D. Muenzner, V. J. Assikis, M. Piette, V. C. Jordan (Robert H. Lurie Comprehensive Cancer Center), G. M. England, M. M. Bilimoria (Department of Surgery), R. Chatterton (Department of Obstetrics and Gynecology), Northwestern University, Chicago, IL; Y. P. Dragan, H. C. Pitot, McArdle Laboratory, University of Wisconsin, Madison.
Correspondence to: V. Craig Jordan, Ph.D., D.Sc., Robert H. Lurie Comprehensive Cancer Center and Northwestern University Medical School, 8258 Olson, 303, E. Chicago Ave., Chicago, IL 60611.
Abstract
Background: Tamoxifen has been shown to promote the growth of human endometrial tumors implanted in athymic mice, and it has been associated with a twofold to threefold increase in endometrial cancer. Toremifene, a chlorinated derivative of tamoxifen, and ICI 182,780, a pure antiestrogen, are two new antiestrogens being developed for the treatment of breast cancer. The effects of these drugs on endometrial cancer are currently unknown. Our objective was to evaluate the effects of toremifene and ICI 182,780 on the growth of human endometrial cancer in athymic mice. Methods: Athymic, ovariectomized mice were implanted with human endometrial tumors and treated with estrogen, tamoxifen, or the new antiestrogens. Results: The effects of tamoxifen and toremifene on the growth of either tamoxifen-stimulated or tamoxifen-naive endometrial tumors in athymic mice were not substantially different. ICI 182,780 inhibited the growth of tamoxifen-stimulated endometrial cancer, in both the presence and the absence of estrogen. Conclusions: Toremifene and tamoxifen produce identical effects in our endometrial cancer models. Therefore, it is possible that toremifene, like tamoxifen, may be associated with an increased incidence of endometrial cancer. In contrast, ICI 182,780 inhibited tamoxifen-stimulated endometrial cancer, both in the presence and in the absence of estrogen, suggesting that this drug may be safe with regard to the endometrium, even if it is used following tamoxifen, and that it may not result in an increased incidence of endometrial cancer. Indeed, it is even possible that ICI 182,780 may prove useful as an adjuvant agent in early stage endometrial cancer. [J Natl Cancer Inst 1998;90:1552-8]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Zhu and J. W. Pollard Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling PNAS, October 2, 2007; 104(40): 15847 - 15851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. L. de Oliveira, H. V. Domingos, G. Cavriani, A. S. Damazo, A. L. dos Santos Franco, S. M. Oliani, R. M. Oliveira-Filho, B. B. Vargaftig, and W. T. de Lima Cellular recruitment and cytokine generation in a rat model of allergic lung inflammation are differentially modulated by progesterone and estradiol Am J Physiol Cell Physiol, September 1, 2007; 293(3): C1120 - C1128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. O'Regan, C. Osipo, E. Ariazi, E. S. Lee, K. Meeke, C. Morris, A. Bertucci, M. A.B. Sarker, R. Grigg, and V. C. Jordan Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin. Cancer Res., April 1, 2006; 12(7): 2255 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Lewis, K. Meeke, C. Osipo, E. A. Ross, N. Kidawi, T. Li, E. Bell, N. S. Chandel, and V. C. Jordan Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen Deprivation J Natl Cancer Inst, December 7, 2005; 97(23): 1746 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Osipo, K. Meeke, H. Liu, D. Cheng, S. Lim, A. Weichel, and V. C. Jordan Trastuzumab Therapy for Tamoxifen-Stimulated Endometrial Cancer Cancer Res., September 15, 2005; 65(18): 8504 - 8513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. I. Apak and M. W. Duffel INTERACTIONS OF THE STEREOISOMERS OF {alpha}-HYDROXYTAMOXIFEN WITH HUMAN HYDROXYSTEROID SULFOTRANSFERASE SULT2A1 AND RAT HYDROXYSTEROID SULFOTRANSFERASE STA Drug Metab. Dispos., December 1, 2004; 32(12): 1501 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al. Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Osipo, C. Gajdos, H. Liu, B. Chen, and V. C. Jordan Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer J Natl Cancer Inst, November 5, 2003; 95(21): 1597 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Dardes, R. M. O'Regan, C. Gajdos, S. P. Robinson, D. Bentrem, A. De Los Reyes, and V. C. Jordan Effects of a New Clinically Relevant Antiestrogen (GW5638) Related to Tamoxifen on Breast and Endometrial Cancer Growth in Vivo Clin. Cancer Res., June 1, 2002; 8(6): 1995 - 2001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. O'Regan, C. Gajdos, R. C. Dardes, A. De Los Reyes, W. Park, A. W. Rademaker, and V. C. Jordan Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice J Natl Cancer Inst, February 20, 2002; 94(4): 274 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Dardes, D. Bentrem, R. M. O'Regan, J. M. Schafer, and V. C. Jordan Effects of the New Selective Estrogen Receptor Modulator LY353381.HCl (Arzoxifene) on Human Endometrial Cancer Growth in Athymic Mice Clin. Cancer Res., December 1, 2001; 7(12): 4149 - 4155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schafer, E.-S. Lee, R. C. Dardes, D. Bentrem, R. M. O'Regan, A. De Los Reyes, and V. C. Jordan Analysis of Cross-Resistance of the Selective Estrogen Receptor Modulators Arzoxifene (LY353381) and LY117018 in Tamoxifen-stimulated Breast Cancer Xenografts Clin. Cancer Res., August 1, 2001; 7(8): 2505 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibutani, A. Ravindernath, I. Terashima, N. Suzuki, Y. R. Santosh Laxmi, Y. Kanno, M. Suzuki, T. I. Apak, J. J. Sheng, and M. W. Duffel Mechanism of Lower Genotoxicity of Toremifene Compared with Tamoxifen Cancer Res., May 1, 2001; 61(10): 3925 - 3931. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. J. Bentrem, R. C. Dardes, H. Liu, J. MacGregor-Schafer, J. W. Zapf, and V. C. Jordan Molecular Mechanism of Action at Estrogen Receptor {{alpha}} of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen Endocrinology, February 1, 2001; 142(2): 838 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Lee, J. M. Schafer, K. Yao, G. England, R. M. O’Regan, A. D. L. Reyes, and V. C. Jordan Cross-Resistance of Triphenylethylene-type Antiestrogens but not ICI 182,780 in Tamoxifen-stimulated Breast Tumors Grown in Athymic Mice Clin. Cancer Res., December 1, 2000; 6(12): 4893 - 4899. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Schafer, E. S. Lee, R. M. O'Regan, K. Yao, and V. C. Jordan Rapid Development of Tamoxifen-stimulated Mutant p53 Breast Tumors (T47D) in Athymic Mice Clin. Cancer Res., November 1, 2000; 6(11): 4373 - 4380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cavalieri, K. Frenkel, J. G. Liehr, E. Rogan, and D. Roy Chapter 4: Estrogens as Endogenous Genotoxic Agents--DNA Adducts and Mutations J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 75 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yao, E.-S. Lee, D. J. Bentrem, G. England, J. I. M. Schafer, R. M. O’Regan, and V. C. Jordan Antitumor Action of Physiological Estradiol on Tamoxifen-stimulated Breast Tumors Grown in Athymic Mice Clin. Cancer Res., May 1, 2000; 6(5): 2028 - 2036. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Lippman and P. H. Brown Tamoxifen Prevention of Breast Cancer: an Instance of the Fingerpost J Natl Cancer Inst, November 3, 1999; 91(21): 1809 - 1819. [Full Text] [PDF]
|
|
|
|
|
|
J. Maenpaa, J. Ellmen, T. Pasanen, and M. Kaukonen Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth J Natl Cancer Inst, June 2, 1999; 91(11): 972 - 973. [Full Text] [PDF]
|
|
|
|
|
|
G. M. Williams Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth J Natl Cancer Inst, April 21, 1999; 91(8): 722 - 722. [Full Text] [PDF]
|
|
|
|
|
|
M. W. DeGregorio, R. O'Regan, and V. C. Jordan Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth • RESPONSE J Natl Cancer Inst, March 3, 1999; 91(5): 474 - 475. [Full Text] [PDF]
|
|